Here is part two of comments from C-suite execs on emerging markets and Asia in the latest quarterly conference calls.
FiercePharma brings you notes on the Asian and emerging markets operations of major drug companies from fourth-quarter earnings calls to explain what C-suite executives are focused on.
With growing competition in emerging markets, Abbott wants to make sure its products stay in the forefront. So, it's rolling out a new branding campaign to cozy up with consumers and amp up its international name recognition.
India-based Cipla has been expanding its manufacturing footprint outside of its base in India and has now made the jump across the Arabian Sea to Yemen.
Diversified conglomerate Danaher emphasized organic growth rather than acquisitions at a recent investor meeting. That's despite much speculation on its M&A appetite following the Medtronic announcement that it will acquire Covidien.
Amid new layoffs and plummeting revenues, the pharma sales force continued to decline in North America and Europe in 2013.
GE Healthcare has developed a discount molecular imaging system for cancer detection, intended for physicians practicing personalized medicine in emerging markets--especially India, where the devicemaker got help designing the system.
The Persian Gulf is the newest emerging market for Big Pharma, the Wall Street Journal reports. Drugmakers have jumped on that opportunity, as evidenced by the number of new plants and distribution facilities they are putting there.
Are the BRIC countries passé in Big Pharma? Not exactly. But multinational pharma's newest trend lies in the Persian Gulf, the Wall Street Journal reports.
Two of the biggest players in Brazil's diagnostics industry are likely to confront major changes in the coming months--both worth noting as global competitors seek to enter one of the largest emerging markets around.